Incyte Corp.
Moat Score — Incyte Corp.
Total Moat Score
13 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Incyte's patent protection on ruxolitinib (Jakafi/Opzelura) and FDA regulatory approvals across multiple indications create strong, legally enforced barriers to entry typical of branded pharmaceuticals. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a mid-cap biopharmaceutical company, Incyte carries heavy R&D and commercialization costs with no structural manufacturing or scale cost advantage over larger pharma competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | While under patent protection, Jakafi and Opzelura command strong branded-drug pricing power, though this is increasingly tempered by newer competing JAK inhibitors and U.S. drug-pricing policy including Medicare price negotiation. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Prescription drug sales exhibit no network effect — a patient's benefit from Jakafi does not increase because other patients also use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Physician familiarity and established treatment protocols for Jakafi create some prescribing inertia, but new entrants like GSK's Ojjaara and Sobi's Vonjo show real ability to win share in the same patient populations. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Myelofibrosis and related myeloproliferative-neoplasm markets are relatively small, limiting the number of viable competitors, but this reflects niche disease economics more than a durable efficient-scale barrier as new mechanisms emerge. |